About_XellSmart biomedical (Suzhou) Co., Ltd

Shize's Development History

XellSmart is committed to providing large-scale, low-cost stem cell therapy solutions for a series of major diseases such as Parkinson's disease for which there is no clinical solution.

Under the leadership of Dr. Li Xiang, XellSmart has independently designed and constructed a 1,600 m2 R&D center and is building a 3,500 m2 production transformation base. Xellsmart has established key technology platforms, such as the reprogramming of iPS cell lines, the iPSC gene editing platform, and the transfer of iPSCs to different sub-type neuronal cells, animal model of Parkinson's disease for evaluation of the safety and efficacy of cell-based drugs, and issued relevant patents.

At present, XellSmart has completed successive rounds financing with total amount over 100 million RMB. The investors includes FreesFund (leading the angel round), Lilly Asia Ventures, Qiming Ventures (co-leading the PreA round), Sequoia China (leading the PreA+ round), YuanBio Venture Capital, TEDA Venture Capital, Tao Capital, NEXT Capital, and Leader Venture Capital.

Team Awards

Striving Continuously to Strengthen Oneself Have Ample Virtue and Carry All Things

Patent

Patent Down to earth, Look up at the starry sky

Article

The beginning is the decisive battle, the beginning is the sprint

Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency: 2017-04
Yang Y, Liu B, Xu J, Wang J, Wu J, Shi C, Xu Y, Dong J, Wang C, Lai W, Zhu J, Xiong L, Zhu D, Li X, Yang W, Yamauchi T, Sugawara A, Li Z, Sun F, Li X, Li C, He A, Du Y, Wang T, Zhao C, Li H, Chi X, Zhang H, Liu Y, Li C, Duo S, Yin M, Shen H, Belmonte JCI, Deng H. Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency. Cell. 2017 Apr 6;169(2):243-257.e25. doi: 10.1016/j.cell.2017.02.005. PMID: 28388409; PMCID: PMC5679268.

Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons: 2015-08
Li X, Zuo X, Jing J, Ma Y, Wang J, Liu D, Zhu J, Du X, Xiong L, Du Y, Xu J, Xiao X, Wang J, Chai Z, Zhao Y, Deng H. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell. 2015 Aug 6;17(2):195-203. doi: 10.1016/j.stem.2015.06.003. PMID: 26253201.

Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State: 2017-08
Li X, Liu D, Ma Y, Du X, Jing J, Wang L, Xie B, Sun D, Sun S, Jin X, Zhang X, Zhao T, Guan J, Yi Z, Lai W, Zheng P, Huang Z, Chang Y, Chai Z, Xu J, Deng H. Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State. Cell Stem Cell. 2017 Aug 3;21(2):264-273.e7. doi: 10.1016/j.stem.2017.05.019. Epub 2017 Jun 22. PMID: 28648365.

Team

In 2021, Dr. Li Xiang took the lead in founding XellSmart, serving as the CEO and CSO. It united Dr. Xiao, Dr. Yan, Manager Qiu and brought together Dr. Chen, Dr. Huang, Dr. Zhu, and VP Yao, a group of experts from science and industry. At present, there are nearly 60 full-time employees, 10 Ph.D./post-doctoral fellows, and more than 65% of the postgraduates with master's degree or above.

Li Xiang (Alias: Xiang Ye)

Founder, Chairman, CEO and CSO of Shize Biopharmaceutical Co., Ltd

Ph.D. in Life Sciences, Peking University
Postdoc at the University of Wisconsin-Madison
Vice Chairman of the Eighth Council of Jiangsu Biotechnology Association
Senior Engineer of Biomedical Engineering, Suzhou City, Jiangsu Province
Suzhou Industrial Park Technology Leading Talent
2021 Golden Award 30 Outstanding Young Innovators in China
Former Senior Scientist of Sana Biotechnology (NASDAQ: SANA)

Angel round investment team

Top investment team working side by side with XellSmart Bio

FreesFund

FREES We firmly believe that being
right is more important than being
easy
FreesFund
Qiming Venture Partners

Enlighten the public with wisdom
and learn with diligence。
Qiming Venture Partners
Lilly Asia Ventures

We fight disease, save lives and
improve human health Provide
industry experience, global
resources and long-term capital.
Lilly Asia Ventures
Sequoia China

Sequoia China, the entrepreneur
behind the entrepreneur, is
committed to discovering and
cultivating [towering trees] in the
industry.
Sequoia China
TEDA Venture Capital

TEDA Tech We believe that
technology creates value.
TEDA Venture Capital
YuanBio Venture Capital

professional focus, steady and
pragmatic.
YuanBio Venture Capital
NEXT Capital

Innovator's first money
Discover the Next Big Thing.
NEXT Capital
Tao Capital

Focus on medical and health
investment to promote the
development of life sciences.
Tao Capital

Culture

Patients first, "Blade" second, shareholders third

Development History

more

In January 2022: In January 2022, XellSmart completed a Pre-A+ round of financing of nearly 100 million RMB.

In January 2022: In January 2022, XellSmart won the 2021 bioBAY "Growth Award".

In December 2021: In December 2021, XellSmart won the winning project of the National Disruptive Technology Innovation Competition.

In December 2021: In December 2021, XellSmart won the Golden Award and the Most Growing Innovative Company in 2021.

In December 2021: In December 2021, Dr. Li Xiang, founder and chairman of XellSmart, was awarded the Golden Award · 2021 China's 30 Outstanding Young Innovators

In October 2021: In October 2021, XellSmart was awarded the 2021 Top 50 Most Innovative Chinese Biopharmaceutical Enterprises.

In September 2021: In September 2021, XellSmart won the first prize in the final of the first Sino-Russian Youth Innovation, Entrepreneurship and Creativity Competition in the pharmaceutical and health industry.

In September 2021: In September 2021, XellSmart biology completed nearly 100 million yuan of pre-A round of financing.

In July 2021: In July 2021, XellSmart was elected as the executive vice-chairman unit of Jiangsu Biotechnology Association.

In June 2021: In June 2021, XellSmart won the excellent project (the highest award) of the Zhangjiang Cell Industry International Summit Roadshow.

In June 2021: In June 2021, XellSmart officially entered the Shanghai Jinling Valley Base.

In June 2021: In June 2021, XellSmart Bio has completed tens of millions of angel round investment.

In May 2021: In May 2021, XellSmart Bio officially announced the establishment.